Methods of Detection of Measurable Residual Disease in AML

Current Hematologic Malignancy Reports
Yi Zhou, B L Wood

Abstract

The presence of measurable ("minimal") residual disease (MRD) after induction and/or consolidation chemotherapy is a significant risk factor for relapse in patients with acute myeloid leukemia (AML). In recognition of the clinical significance of AML MRD, the European LeukemiaNet (ELN) recently recommended the establishment of CR-MRDNegative as a separate category of treatment response. This recommendation represents a major milestone in the integration of AML MRD testing in standard clinical practice. This review article summarizes the methodologies employed in AML MRD detection and their application in clinical studies that provide evidence supporting the clinical utility of AML MRD testing. Future MRD evaluations in AML likely will require an integrated approach combining multi-parameter flow cytometry and high-sensitivity molecular techniques applied to time points during and after completion of therapy in order to provide the most accurate and comprehensive assessment of treatment response.

References

Aug 4, 1999·Proceedings of the National Academy of Sciences of the United States of America·B Vogelstein, K W Kinzler
Aug 30, 2003·Archives of Pathology & Laboratory Medicine·Steven J Kussick, Brent L Wood
Oct 9, 2003·British Journal of Haematology·Elaine Coustan-SmithDario Campana
Dec 16, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Bruce D ChesonUNKNOWN International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards
Jan 22, 2005·The New England Journal of Medicine·Brunangelo FaliniUNKNOWN GIMEMA Acute Leukemia Working Party
Nov 11, 2005·Leukemia·G PereaUNKNOWN Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel
Apr 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hélène LapillonneJudith Landman-Parker
Jun 20, 2007·Proceedings of the National Academy of Sciences of the United States of America·Naoki HosenIrving L Weissman
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Sep 16, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daniela CilloniDavid Grimwade
Jul 14, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Andrea CorbaciogluKonstanze Döhner
Feb 2, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Roland B WalterJohn M Pagel
Mar 9, 2011·Proceedings of the National Academy of Sciences of the United States of America·Max JanRavindra Majeti
May 11, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jan KrönkeKonstanze Döhner
May 19, 2011·Proceedings of the National Academy of Sciences of the United States of America·Isaac KindeBert Vogelstein
May 4, 2012·Leukemia·J J M van DongenUNKNOWN EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708)
Sep 6, 2012·Leukemia·T KalinaUNKNOWN EuroFlow Consortium (EU-FP6, LSHB-CT-2006-018708)
Sep 12, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hiroto InabaDario Campana
May 15, 2013·Methods in Molecular Biology·Brent L Wood

❮ Previous
Next ❯

Citations

Apr 16, 2020·Journal of Leukocyte Biology·Lihui LinLi Li
Jul 7, 2020·American Journal of Hematology·Ibrahim AldossVinod Pullarkat
Nov 18, 2018·Current Hematologic Malignancy Reports·Franklin Fuda, Weina Chen
May 28, 2020·Frontiers in Cell and Developmental Biology·Jennifer M YoestEric J Duncavage
Feb 13, 2021·Frontiers in Oncology·Lok Lam NgaiJacqueline Cloos

❮ Previous
Next ❯

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.